
    
      This is a phase I, double center, randomized, double-blind, single dose and parallel group
      clinical trial . The primary objective is to assess the pharmacokinetic similarity of MV088
      and Prolia® in healthy volunteers. The secondary objectives is to assess the similarity of
      clinical safety and immunogenicity of MV088 and Prolia® in healthy volunteers.
    
  